Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer
Provided By GlobeNewswire
Last update: Aug 19, 2024
Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15 fusion protein, for solid tumor immunotherapy
NASDAQ:SONN (2/21/2025, 8:00:02 PM)
1.44
+0.01 (+0.7%)
Find more stocks in the Stock Screener
